Onco Wiki / Indication

Kaposi sarcoma · line 2 · Paclitaxel monotherapy (Kaposi sarcoma, post-anthracycline)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy2
Trackstandard
Linked regimenREG-PACLITAXEL-KAPOSI
IDIND-KAPOSI-2L-VISCERAL-PACLITAXEL
TypeIndication
Statusreviewed 2026-07-11 | pending_clinical_signoff
DiseasesDIS-KAPOSI
SourcesSRC-NCCN-SKIN-2025

Notes

STUB -- new TREATMENT-intent 2L Indication for DIS-KAPOSI (v0.3 continuation). Introduces new Regimen REG-PACLITAXEL-KAPOSI (reuses the existing DRUG-PACLITAXEL entity). evidence_level set to `low` and strength_of_recommendation to `conditional` specifically because of the unresolved KS-specific dosing gap (see `rationale` and the Regimen's own `notes`) -- NOT because the FDA-approved-2L-status fact itself is uncertain. Not referenced from ALGO-KAPOSI-1L's output_indications (that Algorithm is explicitly scoped to 1L routing); reachable via IND-KAPOSI-1L-VISCERAL-PLD.followed_by. A dedicated 2L algorithm is out of scope for this authoring pass. INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 with position "supports". That source documents only basal-cell/squamous-cell skin cancer (confirmed by direct inspection of its own KB record), not Kaposi sarcoma -- downgraded to "context". The FDA-2L-approval fact is independently supported by the already-verified DRUG-PACLITAXEL entity, not by this citation. Pending two-Clinical-Co-Lead signoff (CHARTER §6.1 -- dev-mode- exempted; safe to merge as draft content, NOT as published/verified clinical advic...

Used By

Algorithms

Disease

Indication